Skip to content
Medical Health Aged Care, Mental Health

Vulnerable patient groups more likely to be prescribed older antiseizure medications following stroke

Monash University 2 mins read
Assortment of pills. Sourced from Unsplash.

A new study from Monash University has found vulnerable patient groups, including those with dementia, psychiatric conditions and patients aged 85 years and older, are more likely than other patient groups to be prescribed older antiseizure medications following ischaemic stroke.

The team of researchers from the Centre for Medicine Use and Safety (CMUS) at the Monash Institute of Pharmaceutical Sciences (MIPS) followed 19,601 people hospitalised with a first ischaemic stroke in Victoria from 2013-2017. Of these people, 989 were dispensed antiseizure medication within 12 months of hospital discharge.

Whilst there was an overall trend toward the dispensing of newer antiseizure medications over time, it was the most vulnerable groups being prescribed older medications, increasing their risk of being exposed to adverse events and drug-drug interactions.

Compared to the general population, people who experience a stroke are at higher risk of developing epilepsy, which is a common and serious neurological disorder characterised by recurrent unprovoked seizures.

CMUS PhD candidate Stella Kim said those aged 60 years and older run a higher risk of developing newly-diagnosed epilepsy after stroke, and therefore optimal medication treatment plans are crucial.

“Antiseizure medications are the main treatment option for controlling seizures after stroke, and treatment should be individualised according to factors such as seizure type, demographic factors, comorbidities and concurrent medications,” said Ms Kim.

“Our study highlights the need for further research into the comparative safety and effectiveness of antiseizure medications.”

Senior author Dr Jenni Ilomaki said “older antiseizure medications are often associated with side-effects and interactions, and it’s concerning these medications were dispensed to vulnerable patient groups arguably at greatest risk of medication-related harm.”

“Our hope is the findings from this study will pave the way for further investigation into the effectiveness and safety of different antiseizure medications in Australia’s most vulnerable groups.”

Quality Use of Medicines and Medicine Safety is Australia’s tenth National Health Priority Area. The findings have been published in Epilepsia Open and were presented at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Halifax Canada.

The full study can be read here.


Contact details:

Kate Carthew - Media and Communications Manager

T: +61 (0) 438 674 814

For more Monash media stories, visit our news and events site  


More from this category

  • Medical Health Aged Care, Mental Health
  • 16/07/2024
  • 07:00
Monash University

How to detect adverse events in older people using psychotropic medicines; Australian researchers name top ten signs and symptoms

A new study led by Monash University has revealed the top ten signs and symptoms to monitor for that may help to identify adverse…

  • Contains:
  • Medical Health Aged Care
  • 16/07/2024
  • 06:00
Monash University

Why early life antibiotic use can increase risk of asthma: a potential prevention for asthma later in life?

Early exposure to antibiotics can trigger long term susceptibility to asthma, according to new research from Monash University. Importantly the research team isolated a molecule produced by gut bacteria that in the future could potentially be trialed as a simple treatment, in the form of a dietary supplement, for children at risk of asthma to prevent them developing the disease. Asthma affects over 260 million people globally and causes around 455,000 deaths annually. In Australia, 2.7 million people live with asthma and for 45% of these people, their asthma is poorly controlled. The research led by Professor Ben Marsland and…

  • Business Company News, Medical Health Aged Care
  • 15/07/2024
  • 11:55
Jane Morgan Management

Heramed Limited (ASX:HMD) and UTS Sign Five-Year Strategic Partnership Focused on Care and Wellbeing of Women and Babies

Melbourne, Australia – 15 July 2024 | Heramed Ltd (ASX: HMD) ("Heramed" or the "Company"), a pioneering medical data and technology company transforming maternity care, is pleased to announce the signing of a five-year Strategic Partnership Agreement (SPA) with the University of Technology Sydney (UTS). This partnership is led by UTS's INSIGHT Health Research Institute, a renowned centre for innovative health solutions. Key Highlights: Strategic Partnership: Heramed and UTS have entered a five-year strategic partnership through the leadership of INSIGHT Health Research Institute, focusing on improving the care and wellbeing of women and babies. Collaboration Scope: UTS, a leading Australian…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.